Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, ...

Alarmed by the color and frequency of the blood in her stool, Mahon was referred to a GI doctor who initially thought she had an autoimmune disease. “Once I got the colonoscopy, she told me that she ...

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

Colon cancer is steadily rising in cases, and while there are many symptoms a person can experience, one man only had one ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

A new study has found that taking a small daily dose of aspirin could help stop colon cancer from returning in some patients.

DNA testing may inform treatment decisions and predict outcomes of adjuvant chemotherapy in patients with stage II-III colorectal cancer.

Dwyane Wade reflected on having a cancerous tumor removed from his kidney as well as 40 percent of the organ itself after ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...